BCR-ABL tyrosinase kinase inhibitors (TKI) are effective against CML; however, these agents are unable to eliminate quiescent leukaemia stem cells (Ref. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.